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 Founded in 1961 with a fi rst director (Professor J.E.Roberts 1961–1963), it 
 developed under the direction of Professor E S Williams (1963–1985) and 
matured into international recognition under the director Professor Peter J. Ell 
(1986–2011). By its 50th anniversary, it already listed over 1000 peer reviewed 
publications, major Text Books and contributions to teaching. A signifi cant 
 milestone was achieved when the Editor of The Lancet commissioned the INM 
to edit 6 articles describing the clinical practice of Nuclear Medicine in subse-
quent 6 weekly issues of this premier medical publication (August 21 to 
September 25, 1999).
 The physiological nature of the radionuclide tracer methodology is already trans-
parent in the contents of the fi rst 1961 INM Handbook for clinicians, highlighting 
the available procedures (Fig.  6.1 ). These included topographic surveys of the thy-
roid, liver, brain, haematological tests, such as red cell and platelet cell survival, 
plasma volume, vitamin B12 and iron absorption, iron clearance, as well as, inter 
alia, body composition studies with exchangeable sodium and potassium, extracel-
lular fl uid volume and total body water measurements. Thyroid function tests were 
part of the menu, including the assay of T4, the TSH stimulation test and perchlorate 
discharge testing. 
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 Leading the speciality in the UK, the INM developed with the Royal Postgraduate 
Medical School and the Institute of Cancer Research, the fi rst intercollegiate Master 
of Science Course (MSc) in Nuclear Medicine. This gained wide recognition, and 
at the INM, some 100 MSc graduates, mostly from overseas, obtained their diploma 
over the ensuing years. 
 Fig. 6.1  1961 INM Handbook 
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 The outstanding academic achievement has to be the development of radioim-
munoassay and saturation analysis, under Professor Roger P. Ekins (deputy director 
1968–1981), changing the world of analytical biochemistry, endocrinology and 
medicine. A Fellow of the Royal Society, Ekins received the Department of Health’s 
Lifetime Achievement Award in 2011. 
 Other signifi cant early contributions are highlighted below. 
 Edward Williams, as a life long mountaineer, investigated electrolyte function, 
aldosterone excretion and potassium retention at highest altitudes, publishing in 
Nature, inter alia, in 1961. A. Todd-Pokropek and D. Keeling designed and built in 
1969 the fi rst 3 D scanner in Europe, a true precursor of single photon emission 
tomography (SPET). The subsequent development of single photon emission 
tomography at the INM became a major success story, the Institute leading the UK 
in the clinical applications of the 3 D radionuclide imaging technology (with major 
peer reviewed output emerging from 1979 onwards). 
 The fi rst UK patient studies with Gallium-67 citrate in 1970 in lymphoma by 
David Keeling and the development of deconvolution analysis in renography by 
Keith Britton and Nicholas Brown in 1968/1969, require to be highlighted here. 
 As novel radionuclide labelled tracers began to enable a transition to be made 
from mostly anatomical representation of organs (for example altered blood brain 
barrier imaging with pertechnetate, or liver imaging, even when mediated, for 
example, by Kupfer cell uptake) towards more pathophysiological meaningful path-
way representations, the INM was able to keep at the forefront of what later would 
became known as molecular imaging. Hence the INM led the imaging with lypo-
philic tracers such as HMPAO for blood fl ow studies of the brain (1985), receptor 
imaging probes such as methoxybenzamide for imaging the D2/D3 dopaminergic 
system (1990), iomazenil for imaging the benzodiazepine receptor (1997), and 
investigating, inter alia, probes for the NMDA receptor (2003), for cell proliferation 
(2003), the 5-HT2A receptor (2006), the sigma-1 receptor (2006), and the soma-
tostatin receptor in 2008. 
 A further fi rst for the UK was the INM introduction of X-Ray based dual photon 
absorptiometry, in late 1988. This completely changed the accuracy and precision 
of bone mineral density measurements, the technology rapidly diffusing throughout 
the UK, with the newly established National Osteoporosis Society. In a short period 
of time, several seminal peer reviewed publications arose from the staff at the INM, 
such as in  BJR 1989,  BJR 1990,  EJNM 1991. 
 By 1986, almost 25 % of all diagnostic procedures carried out at the INM 
involved the investigation of the heart (myocardial perfusion, wall motion, and ven-
tricular ejection). The INM developed pharmacological stress testing with adenos-
ine and dobutamine, with peer reviewed data in  BHJ 1989,  JACC and  AHJ in 1991 
and  Circulation in 1998. Richard Underwood undertook a landmark study, with one 
the very few cost benefi ts studies published in the fi eld of Nuclear Medicine 
( European Heart Journal 1999). A further fi rst was the use of PETCT and Rb82, 
combining CT angiography with PET based perfusion, for myocardial studies 
(Groves 2007) followed by the introduction to the UK of solid state technology and 
dual radionuclide myocardial perfusion by Simona Ben Haim in 2010 (Fig.  6.2 ).
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 From its early beginnings in the 60’s and until the present time, the INM was 
always committed and involved in the development of imaging probes to study the 
brain, in its complexity and varied pathologies. Whilst a more detailed description 
is to be found in another chapter of this anniversary book, it is useful to recall the 
use of brain blood barrier scanning in the evaluation of patients with subdural 
 haematoma, stroke, space occupying masses, the use of I123 and Tc99m labelled 
probes for the investigation of refractory temporal epilepsy, the dementias 
(Pick’s and especially Alzheimer type) and the use of dopamine transporter probes 
for the investigation of essential tremor and Parkinsonian syndromes.(peer reviewed 
publications in, inter alia,  The Lancet 1985,  Lancet 1986,  Lancet 1989,  BMJ 1992, 
 Lancet 1992 (Fig.  6.3 ).
 From 1998 onwards, a major program in surgical oncology was developed at the 
INM It was based on a very simple but attractive concept, namely that lymph node 
progression in several major cancers is predictable and can be investigated when 
patients present with early disease. So the concept of the sentinel node and its biopsy 
was investigated in detail by the surgical and nuclear medicine teams (M. Keshtgar, 
W. Waddington, and P. Ell), with special emphasis of staging patients with early 
breast carcinoma. This novel technique proved to be extraordinarily effective, spar-
ing invasive axillary surgery in 2 out of 3 patients presenting early with their 
1972 2010 1990
 Fig. 6.2  Shows the evolving NM imaging technologies of the heart, from early K-42 studies in 
the 70s, to phase and amplitude with EF data in the 90s and Rb-52 PETCT in 2010 
 Fig. 6.3  Showing early BBB imaging, cerebral blood fl ow, MR co-registered benzodiazepine 
imaging and dopamine transporter imaging 
 
 
J. Bomanji and P.J. Ell
43
condition. The INM started a major teaching program in the clinical skills lab, over 
100 attendees benefi ted from their exposure to this training program, a Text Book 
and a CD was published and a substantial contribution to the literature ensued (inter 
alia,  Lancet 1998,  Lancet 1999,  Lancet Oncology 2002,  J. National Cancer Institute 
2006, and  EJNM 2000,  European J. Surgical Oncology 2004). 
6.1  UK Introduction of PETCT and PETMR 
 INM was fi rst to introduce these major disruptive technologies to the UK (Ell PJ,von 
Schulthess GK. PET/CT: a new road map.  Eur J Nucl Med Mol Imaging . Jun; 
29(6):719–20, 2002) . The fi rst UK patient to benefi t from this new development 
was investigated with PETCT on the 17th of January 2002! PET/CT led to a dra-
matic increase in the acceptance and utility of the PET clinical programme – in the 
3 months of September, October and November 2002, 402 patients were investi-
gated with this unique technology. In a decade, over 100 peer reviewed INM publi-
cations were published (Fig.  6.4 ).
 The management of patients with cancer changed, early staging and early treat-
ment response have become paradigms of the clinical usefulness of this approach. 
As a multimodality imaging investigation, the referral base was rapidly extended to 
 Fig. 6.4  Shows a range of labelled imaging probes which have been investigated at the INM 
with PETCT 
 
6 The Institute of Nuclear Medicine London
44
include the assessment of cardiac function and coronary artery disease, and most 
recently, with PETMR, the early demonstration of amyloid plaque deposition in 
patients with cognitive impairment (early MID or developing AD). The Institute 
introduced PETMR to the UK in April 2012. 
6.2  The Institute of Nuclear Medicine: National 
and International Impact on Standards, Teaching, 
Publishing and Organisation 
 Already mentioned above, the INM was a major contributer to an international rec-
ognised MSc course in Nuclear Medicine. Edward Williams, graduated in physics 
and medicine and became the fi rst Chairman of ARSAC, the national body which 
issues medical certifi cates for safe practice. He was involved in writing much of the 
regulations which deliver safe radiation practice. Keshtgar, Waddington and Ell 
made a signifi cant contribution to surgical standard setting for the practice of senti-
nel lymph node biopsy, now adopted by the Royal College of Surgeons as best 
practice. Peter Ell became Editor of the European Journal of Nuclear Medicine from 
1988 to 2003, a major publication in the imaging fi eld, raising the standard, profi le 
and impact factor of this publication Keith Britton, whilst Consultant Physician in 
charge at INM, brought, as Congress President, the joint Congress of two European 
Societies of Nuclear Medicine to London in 1985. Britton and Ell wrote the new 
Bye Laws of the newly constituted single European Association of Nuclear 
Medicine, and were 2 of the 4 co-signatures founding the Association in 1985. Peter 
Ell became its President from 1994 to 1996. During his tenure, the European School 
of Nuclear Medicine was established. 
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 Dr. J Bomanji  Dr. J Bomanji completed his graduation in 1980. He did his post-graduation at 
St Bartholomew’s Hospital where he completed his Masters and PhD in Nuclear Medicine in 
1987. He was appointed as Consultant in Nuclear Medicine at St Bartholomew’s Hospital in 
1990 and then moved to The Middlesex Hospital in 1993, which is now part of the UCLH NHS 
Foundation Trust. Currently, he is the Clinical Lead and Head of Clinical Department at the 
Institute of Nuclear Medicine. His main interests are in the diagnostic and therapeutic application 
of nuclear medicine techniques in oncology, nephrology/urology, cardiology and neurology for 
benign and malignant disease. 
 He has contributed and published more than 200 research and clinical papers in peer-reviewed 
journals, authored numerous book chapters and is the editor of Nuclear Medicine in Oncology. He 
is assistant editor and advisory editor of various journals in the fi eld of nuclear medicine. 
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